Daniel Camilo Aguirre-Acevedo1, Fabian Jaimes-Barragán2, Eliana Henao3, Victoria Tirado3, Claudia Muñoz3, Eric M Reiman4, Pierre N Tariot4, Jessica B Langbaum4, Francisco Lopera3. 1. Grupo de Neurociencias de Antioquia,Grupo Académico de Epidemiología Clínica,School of Medicine,Medical Research Institute,University of Antioquia,Medellín,Colombia. 2. Grupo Académico de Epidemiología Clínica and Research Unit,Hospital Pablo Tobón Uribe,School of Medicine,University of Antioquia,Hospital Pablo Tobón Uribe,Medellín,Colombia. 3. Grupo de Neurociencias de Antioquia,School of Medicine,University of Antioquia,Medellín,Colombia. 4. Banner Alzheimer's Institute,Arizona,USA.
Abstract
BACKGROUND: This study aimed to determine Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Neuropsychological Assessment Battery total score diagnostic accuracy in the diagnosis of mild cognitive impairment (MCI) and dementia in familial Alzheimer's disease (FAD) with E280A mutation on presenilin-1 gene (PSEN1). METHODS: A cross-sectional study was conducted in a cohort of PSEN1 E280A carriers and non-carriers assessed between January 1995 and February 2013. During the first neuropsychological assessment, 76 were having dementia, 46 had MCI, and 1,576 were asymptomatic. CERAD cut-off points were established for MCI and dementia using a Receiver Operating Characteristics (ROC) analysis, and were further analyzed according to education level in two groups: low education level (eight years or less), and high education level (over eight years). RESULTS: The area under curve-ROC CERAD total score for dementia was 0.994 (95% CI = 0.989-0.999), and that for MCI was 0.862 (95% CI = 0.816-0.908). The dementia diagnosis cut-off point for the low education group was 54, (98.4% sensitivity, 92.6% specificity), and that for the high education group was 67 (100% sensitivity, 94.1% specificity). The MCI diagnosis cut-off point for the low education group was 66 (91.2% sensitivity, 56.4% specificity), and that for the high education group was 72 (91.7% sensitivity, 76.3% specificity). CONCLUSIONS: The CERAD total score is a useful screening tool for dementia and MCI in a population at risk of FAD.
BACKGROUND: This study aimed to determine Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Neuropsychological Assessment Battery total score diagnostic accuracy in the diagnosis of mild cognitive impairment (MCI) and dementia in familial Alzheimer's disease (FAD) with E280A mutation on presenilin-1 gene (PSEN1). METHODS: A cross-sectional study was conducted in a cohort of PSEN1E280A carriers and non-carriers assessed between January 1995 and February 2013. During the first neuropsychological assessment, 76 were having dementia, 46 had MCI, and 1,576 were asymptomatic. CERAD cut-off points were established for MCI and dementia using a Receiver Operating Characteristics (ROC) analysis, and were further analyzed according to education level in two groups: low education level (eight years or less), and high education level (over eight years). RESULTS: The area under curve-ROC CERAD total score for dementia was 0.994 (95% CI = 0.989-0.999), and that for MCI was 0.862 (95% CI = 0.816-0.908). The dementia diagnosis cut-off point for the low education group was 54, (98.4% sensitivity, 92.6% specificity), and that for the high education group was 67 (100% sensitivity, 94.1% specificity). The MCI diagnosis cut-off point for the low education group was 66 (91.2% sensitivity, 56.4% specificity), and that for the high education group was 72 (91.7% sensitivity, 76.3% specificity). CONCLUSIONS: The CERAD total score is a useful screening tool for dementia and MCI in a population at risk of FAD.
Authors: Clara Vila-Castelar; Kathryn V Papp; Rebecca E Amariglio; Valeria L Torres; Ana Baena; Diana Gomez; Jorge Rendon; Aubryn Samaroo; Francisco Lopera; Dorene M Rentz; Yakeel T Quiroz Journal: Clin Neuropsychol Date: 2019-12-18 Impact factor: 3.535
Authors: Valeria L Torres; Clara Vila-Castelar; Yamile Bocanegra; Ana Baena; Edmarie Guzmán-Vélez; Daniel C Aguirre-Acevedo; Victoria Tirado; Claudia Munoz; Eliana Henao; Sonia Moreno; Margarita Giraldo; Natalia Acosta; Silvia Rios Romenets; Jessica B Langbaum; William Cho; Eric M Reiman; Pierre N Tariot; Monica Rosselli; Yakeel T Quiroz; Francisco Lopera Journal: Appl Neuropsychol Adult Date: 2019-06-23 Impact factor: 2.248
Authors: Joshua T Fox-Fuller; Heirangi Torrico-Teave; Federico d'Oleire Uquillas; Kewei Chen; Yi Su; Yinghua Chen; Michael Brickhouse; Justin S Sanchez; Cinthya Aguero; Heidi I L Jacobs; Olivia Hampton; Edmarie Guzmán-Vélez; Clara Vila-Castelar; Daniel C Aguirre-Acevedo; Ana Baena; Arabiye Artola; Jairo Martinez; Celina F Pluim; Sergio Alvarez; Martin Ochoa-Escudero; Eric M Reiman; Reisa A Sperling; Francisco Lopera; Keith A Johnson; Bradford C Dickerson; Yakeel T Quiroz Journal: Alzheimers Dement (Amst) Date: 2021-09-14
Authors: Joshua T Fox-Fuller; Arabiye Artola; Kewei Chen; Margaret Pulsifer; Dora Ramirez; Natalia Londono; Daniel C Aguirre-Acevedo; Clara Vila-Castelar; Ana Baena; Jairo Martinez; Joseph F Arboleda-Velasquez; Jessica B Langbaum; Pierre N Tariot; Eric M Reiman; Francisco Lopera; Yakeel T Quiroz Journal: JAMA Netw Open Date: 2021-08-02
Authors: Jorge I Vélez; Luiggi A Samper; Mauricio Arcos-Holzinger; Lady G Espinosa; Mario A Isaza-Ruget; Francisco Lopera; Mauricio Arcos-Burgos Journal: Diagnostics (Basel) Date: 2021-05-17